Biotech | March 16, 2022
Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
The new centre will comprise a team of 50 highly experienced specialists
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
The company will collaborate with U.S.-based colleagues to help life sciences companies improve commercial effectiveness
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The Ahmedabad based hospital in association with Sankalp India Foundation had established the BMT unit in 2017
Subscribe To Our Newsletter & Stay Updated
